pioglitazone has been researched along with Critical Illness in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0." | 9.41 | Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023) |
| " Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0." | 5.41 | Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| McClelland, TJ | 1 |
| Fowler, AJ | 1 |
| Davies, TW | 1 |
| Pearse, R | 1 |
| Prowle, J | 1 |
| Puthucheary, Z | 1 |
| Kaplan, JM | 1 |
| Zingarelli, B | 1 |
| Krallman, K | 1 |
| Tang Girdwood, S | 1 |
| Lagory, D | 1 |
| Mizuno, T | 1 |
| Fei, L | 1 |
| Wong, HR | 1 |
| Vinks, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock[NCT01352182] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We examined the effect of pioglitazone Area under the curve on IL-6 in patients receiving pioglitazone only. (Control subjects did not receive pioglitazone). The pharmacokinetic endpoint was area under the curve (AUC) total/days of pioglitazone administration (NCT01352182)
Timeframe: Evaluation of inflammatory biomarkers will be obtained prior to dosing for the first five days of the study
| Intervention | ng/ml (Least Squares Mean) |
|---|---|
| Pioglitazone Hydrochloride | -1.4425 |
| Normal Standard Care | NA |
The number of hypoglycemic events in pioglitazone vs standard care. Hypoglycemia was defined as blood glucose level that remains <40mg/dl despite dextrose bolus treatment. (NCT01352182)
Timeframe: Assessement over five days
| Intervention | events (Number) |
|---|---|
| Pioglitazone Hydrochloride | 0 |
| Normal Standard Care | 0 |
Pioglitazone concentration as the total area under curve divided by the number of days receiving the drug in subjects who took the drug by mouth versus by naso-gastric tube (NCT01352182)
Timeframe: five days
| Intervention | ng*h/ml (Mean) |
|---|---|
| Pioglitazone Hydrochloride by Mouth | 5363 |
| Pioglitazone Hydrochloride by Nasogastric Tube | 1052 |
ALT levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | U/L (Median) |
|---|---|
| Pioglitazone Hydrochloride | 21.5 |
| Normal Standard Care | 24.5 |
BUN levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 7.5 |
| Normal Standard Care | 10 |
Creatinine levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 0.72 |
| Normal Standard Care | 0.415 |
1 review available for pioglitazone and Critical Illness
| Article | Year |
|---|---|
Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review.
Topics: Adult; Critical Illness; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone | 2023 |
1 trial available for pioglitazone and Critical Illness
| Article | Year |
|---|---|
Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial.
Topics: Critical Illness; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Sepsis | 2018 |